Reviewing Bioasis Technologies (OTCMKTS:BIOAF) and Pyxis Oncology (NASDAQ:PYXS)

Bioasis Technologies (OTCMKTS:BIOAF) and Pyxis Oncology (NASDAQ:PYXS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Profitability

This table compares Bioasis Technologies and Pyxis Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioasis Technologies	N/A	N/A	N/A
Pyxis Oncology	N/A	-135.60%	-85.00%

Institutional and Insider Ownership

39.1% of Pyxis Oncology shares are held by institutional investors. 10.6% of Pyxis Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Bioasis Technologies has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Bioasis Technologies and Pyxis Oncology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioasis Technologies	0	0	0	0	0.00
Pyxis Oncology	1	1	6	0	2.63

Pyxis Oncology has a consensus price target of $6.83, suggesting a potential upside of 199.71%. Given Pyxis Oncology’s stronger consensus rating and higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than Bioasis Technologies.

Valuation & Earnings

This table compares Bioasis Technologies and Pyxis Oncology”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioasis Technologies	N/A	N/A	N/A	N/A	N/A
Pyxis Oncology	$13.86 million	10.42	-$79.62 million	($1.31)	-1.74

Bioasis Technologies has higher earnings, but lower revenue than Pyxis Oncology.

Summary

Pyxis Oncology beats Bioasis Technologies on 7 of the 9 factors compared between the two stocks.

About Bioasis Technologies

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.

About Pyxis Oncology

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.